FH and hereditary leiomyomatosis and renal cell cancer: Moreover, our study reviewed and analyzed the efficacy of immunotherapy in HLRCC patients and suggested that immunotherapy is an effective therapeutic option for HLRCC regardless of the form of FH germline mutation.